Generic entry in 2026 is market-specific rather than global. Important examples include sitagliptin products and tofacitinib in the United States, while semaglutide generics are entering selected markets outside the United States.
Answer
A patent expiry does not automatically mean that a generic drug will launch immediately. Regulatory approval, secondary patents, exclusivity, litigation settlements, manufacturing readiness, and commercial strategy can all change the market-entry date.
Notable 2026 developments include:
• Sitagliptin: FDA granted first generic approvals for Januvia and certain sitagliptin/metformin products in late 2025, with U.S. availability governed by exclusivity and settlement-related launch dates extending into 2026.
• Tofacitinib: Generic competition for Xeljanz has been expected or initiated around 2026 following relevant U.S. patent and settlement timelines.
• Semaglutide: Generic versions of Ozempic- or Wegovy-related semaglutide products are entering selected markets such as Canada, India, and Brazil in 2026. U.S. generic semaglutide is not expected in 2026 because U.S. protections differ.
Other drugs may receive first generic approval during 2026 without becoming immediately available. FDA explicitly notes that an approved generic is not necessarily marketed on its approval date.
For accurate forecasting, companies should check the FDA Orange Book, Paragraph IV certification data, approval letters, litigation settlements, and manufacturer launch announcements. International planning requires separate patent and regulatory assessments for every country because a product may be generic in one market while remaining protected in another.

Trust Our Expert Answers?

